Synbiotic therapy increases eradication rate in Helicobacter pylori eradication

Basit Öğe Kaydı
dc.contributor.authorŞahin Ö.
dc.contributor.authorYeşil A.
dc.contributor.authorŞenateş E.
dc.contributor.authorAkdoğan M.F.
dc.contributor.authorKonür S.
dc.contributor.authorErdem E.
dc.contributor.authorDal M.S.
dc.date.accessioned2024-04-24T18:45:47Z
dc.date.available2024-04-24T18:45:47Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Probiotics are used in combinations of H. pylori eradication regimens with variable results. Many strains tested had shown positive effects on side effect profiles. However, a clear effect on eradication rate is studied thoroughly. We aimed to investigate the beneficial effect of a synbiotic combination in clarithromycin-based triple eradication therapy. Methods: Ninety-two patients who were infected with H. pylori (confirmed via endoscopic biopsy) were randomized into two groups: those undergoing standard triple treatment (control group (rabeprozol plus amoksisilin plus clarithromycin bid) n=49) and those receiving symbiotic (triple plus symbiotic bid group n=43). The symbiotic product contained lactobacillus, bifidobacterium and enterococcus. The 13C-breath test was performed at least 6 weeks after completing both therapy regimens. Results: In the synbiotic group, 3 of the patients complained of metallic taste (7.0%), 1 complained of diarrhea (2.3%), 3 had nausea (7.0%), 2 had gas (4.7%), 3 experienced vomiting (7.0%) and 1 had constipation (2.3%). In the control group, 3 of the patients experienced a metallic taste (6.3%), 7 had diarrhea (14.6%), 5 had nausea (10.4%), 3 had intestinal bloating (6.3%), 3 experienced vomiting (6.3%) and 1 had constipation (2.1%). There was no significant difference between the two groups. However, side effect intensity and eradication rates were significant different between the groups (p<0.05). The eradication rate in the synbiotic group was 88.4%, while it was 68.8% in the control group (p<0.05). Conclusion: The addition of synbiotic to triple therapy decreases the rate of antibiotic-related side effects. It also increases H. pylori eradication rates in clarithromycin-based triple therapy.en_US
dc.identifier.endpage573en_US
dc.identifier.issn0393-6384
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84886065162
dc.identifier.scopusqualityN/A
dc.identifier.startpage569en_US
dc.identifier.urihttps://hdl.handle.net/11468/24875
dc.identifier.volume29en_US
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherActa Medica Mediterraneaen_US
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBifidobacteriaen_US
dc.subjectEradicationen_US
dc.subjectHelicobacter Pylorien_US
dc.subjectLactobacillusen_US
dc.subjectProbioticsen_US
dc.subjectSynbioticsen_US
dc.titleSynbiotic therapy increases eradication rate in Helicobacter pylori eradicationen_US
dc.titleSynbiotic therapy increases eradication rate in Helicobacter pylori eradication
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu